MAP1LC3B and breast cancer: Furthermore, the DR-BC cells were pretreated with 12 mmol/L of autophagy inhibitor 3-methyladenine (3-MA) for 24 h, and we found that the effects of high-dose doxorubicin treatment on LC3B-II/I ratio and p62 expressions in DR-BC cells were abrogated by co-treating cells with 3-MA (Fig. 2i-l), indicating that 3-MA abrogated high-dose doxorubicin-induced autophagy in DR-BC cells.